

Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of H. pylori

メタデータ	言語: eng 出版者: 公開日: 2021-03-18 キーワード (Ja): キーワード (En): 作成者: Furuta, Takahisa, Yamade, Mihoko, Kagami, Takuma, Suzuki, Takahiro, Higuchi, Tomohiro, Tani, Shinya, Hamaya, Yasushi, Iwaizumi, Moriya, Miyajima, Hiroaki, Umemura, Kazuo, Osawa, Satoshi, Sugimoto, Ken メールアドレス: 所属:
URL	http://hdl.handle.net/10271/00003789

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 International License.



Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of *H. pylori*

Takahisa Furuta¹, Mihoko Yamade², Takuma Kagami², Takahiro Suzuki², Tomohiro Higuchi², Shinya Tani³, Yasushi Hamaya², Moriya Iwaizumi⁴, Hiroaki Miyajima², Kazuo Umemura^{1,5}, Satoshi Osawa³, Ken Sugimoto²

¹Center for Clinical Research, ²First Department of Medicine, ³Department of Endoscopic and Photodynamic Medicine, ⁴Department of Clinical Laboratory Medicine, ⁵Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Present address of corresponding author: Takahisa Furuta M. D., Ph.D.
Center for Clinical Research, Hamamatsu University School of Medicine
1-20-1, Handa-Yama, Higashi-Ku, Hamamatsu, 431-3192, Japan
E-mail: furuta@hama-med.ac.jp

Key words: *Helicobacter pylori*, clarithromycin-resistant, dual therapy

Abbreviations: *H. pylori* = *Helicobacter pylori*, MIC = minimum inhibitory concentration, PBP = binding protein, PPI = Proton pump inhibitor, rRNA = ribosomal ribonucleic acid, VA = vonoprazan and amoxicillin, VAC = vonoprazan, amoxicillin and clarithromycin

Abstract

Suzuki et al. reported that the VA-Dual therapy was better at eradicating the clarithromycin-resistant strains of *H. pylori* than the VAC-Triple therapy. We infer that pharmacodynamic antagonism between clarithromycin and amoxicillin underly this phenomenon.

Letter

We read the manuscript written by Suzuki et al [1] with interest. They reported that the eradication rate of *H. pylori* attained by the dual therapy with vonoprazan and amoxicillin (VA-Dual) was almost the same as that attained by the triple therapy with vonoprazan, amoxicillin and clarithromycin (VAC-Triple) as previously reported by us [2]. The most interesting point in this paper was that the VA-Dual therapy was superior to VAC-Triple therapy in eradicating the clarithromycin-resistant strains of *H. pylori*. In this regard, the authors consider the possibilities of the type I error, the difference in the proportion of amoxicillin-resistant strains, and the excessive inhibition of gastric acid secretion caused by the interaction between clarithromycin and vonoprazan. We have another opinion on this phenomenon. We infer that pharmacodynamic antagonism between clarithromycin and amoxicillin underly this phenomenon. In other bacteria, the combination of amoxicillin and clarithromycin has been reported antagonistic [3, 4]. The target of amoxicillin is the penicillin binding protein (PBP), which is the enzyme involved in biosynthesis of bacterial cell wall. When *H. pylori* grows, the expression of PBP is enhanced, which means that the expression of target of amoxicillin is increased, resulting that the bactericidal effect of amoxicillin is enhanced. On the contrary, when the growth of *H. pylori* is inhibited, the expression of PBP is decreased. In this situation, the bactericidal effect of amoxicillin is decreased because the expression of target of amoxicillin is decreased. Clarithromycin is known as the inhibitor of rRNA, indicating that clarithromycin inhibits the protein synthesis including PBP. Then, the sensitivity to amoxicillin is decreased by clarithromycin.

However, if the patient is infected with clarithromycin-sensitive strains, there is no problem because they can be killed by clarithromycin. However, in cases infected with clarithromycin-resistant strains of *H. pylori*, there might be some problems. MIC

ranges of clarithromycin-resistant strains of *H. pylori* are very wide (e.g., from 1 µg/ml to >32 µg/ml). In cases infected with clarithromycin-weakly resistant strains of *H. pylori*, clarithromycin will work halfway. Although *H. pylori* strains cannot be killed by clarithromycin, the inhibitory effect of clarithromycin on rRNA may affect the subsequent protein synthesis including PBP, leading to the reduced sensitivity to amoxicillin.

The eradication rates attained by a PPI, amoxicillin and clarithromycin were reportedly very low in patients infected with clarithromycin-resistant strains of *H. pylori*[5, 6], although amoxicillin resistant strains of *H. pylori* are rare in Japan. The present study by Suzuki et al. accounts for the poor eradication rates by the triple therapy with a PPI, amoxicillin and clarithromycin in patients infected with clarithromycin-resistant strains of *H. pylori*. These clinical studies have suggested that clarithromycin not only does not work as antibiotics, but also has an adverse effect on the action of other antibiotics in cases infected with clarithromycin-resistant strains of *H. pylori*. This paper has suggested that the importance of selecting appropriate antibiotics according to the susceptibility again from another point of view.

References

1. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line *Helicobacter pylori* treatment: a multicentre randomised trial in Japan. *Gut* 2020.
2. Furuta T, Yamade M, Kagami T, et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of *Helicobacter pylori*. *Digestion* 2019:1-9.
3. Drago L, Nicola L, Rodighiero V, et al. Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in *Streptococcus pneumoniae*. *The Journal of antimicrobial chemotherapy* 2011, 66(4):845-849.
4. Medscape: Drug Interaction Checker. <https://referencemedscape.com/drug-interactionchecker>.
5. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant *Helicobacter pylori* using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2002, 16(11):1933-1938.
6. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of *Helicobacter pylori*

infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2003, 17(2):259-264.